A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis)
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Pelabresib (Primary) ; Ruxolitinib (Primary)
- Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders
- Focus Proof of concept; Therapeutic Use
- Acronyms MANIFEST
- Sponsors Constellation Pharmaceuticals
- 23 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Oct 2024.
- 23 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Oct 2024.
- 12 Dec 2023 Results ( (n=78 at data cut off July 29, 2022 from Arm 3) assessing the minimal clinically important difference (MCID) of change in TSS as a continuous endpoint, based on data from JAKi treatment-naive pts with MF treated with pelabresib and ruxolitinib presented at the 65th American Society of Hematology Annual Meeting and Exposition